Resumen

AVILA CABRERA, Onel M. et al. Adverse reactions to imatinib as second-line drug in patients with chronic myeloid leukemia. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.3, pp. 223-227. ISSN 1561-2996.

Imatinib is a synthetic inhibitor of kinase-tyrosine used in the treatment of chronic myeloid leukemia (CML) and also is considered as the first-line drug for the treatment of this entity. The commonest side effects include: nausea, musculoskeletal pains, diarrhea, cutaneous eruption, fatigue and myelosuppression mainly at the expense of granulopoiesis line. A study was conducted in 43 adult patients (23 females and 20 males) presenting with CML pH⁺ in chronic phase, seen in the Hematology and Immunology Institute and in other Hematology services in our country. All cases showed resistance and intolerance to treatment with recombinant Alfa-Interferon (INFα) and Imatinib therapy (400 mg/day) from April, 2003 to July, 2008. The 48,8% of patients have not adverse reactions. The more frequent non-hematologic side effects include bone, muscular or both pain (23%), edema (23,3%); skin hypopigmentation (20,9%), and subcutaneous nodules (11,6%). In hematological reactions are included the drug-hemolytic anemia (14%) drug-immune anemia, drug immune thrombocytopenia (11,6%) and bicitopenia ( 9,3%).

Palabras clave : Chronic myeloid leukemia; Imatinib; adverse reactions.

        · resumen en Español     · texto en Español     · Español ( pdf )